Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

The drug was particularly effective in breast cancers with a mutation in the ESR1 gene, which encodes estrogen receptors, ...

The Biden administration has called for Medicare and Medicaid to expand coverage of weight-loss drugs for people struggling ...

B reast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s ...

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast ...

The efficacy data could help cushion Ibrance's losses of market share to Kisqali, a similar drug from Novartis.

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

This article was updated on Dec. 4 at 4:43 p.m. During almost two-and-a-half hours of debate on Wednesday, nearly all of the court’s conservative majority expressed skepticism about a challenge to ...

Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

The Beachbody Company, Inc. (NYSE: BODI) (“BODi” or the “Company”), a leading fitness and nutrition company, today announced ...